A Dual-Bioresponsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Dual-Bioresponsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade
Authors
Keywords
-
Journal
ADVANCED MATERIALS
Volume -, Issue -, Pages 1806957
Publisher
Wiley
Online
2019-03-12
DOI
10.1002/adma.201806957
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Core–Shell Microneedle Gel for Self-Regulated Insulin Delivery
- (2018) Jinqiang Wang et al. ACS Nano
- In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
- (2018) Chao Wang et al. Science Translational Medicine
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
- (2018) Qian Chen et al. Nature Nanotechnology
- Strategies of Combination Drug Delivery for Immune Checkpoint Blockades
- (2018) Huitong Ruan et al. Advanced Healthcare Materials
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Control of muscle formation by the fusogenic micropeptide myomixer
- (2017) Pengpeng Bi et al. SCIENCE
- DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer
- (2016) Krista P. Terracina et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
- (2016) Axel Hoos NATURE REVIEWS DRUG DISCOVERY
- Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
- (2016) Qian Chen et al. Nature Communications
- Azacitidine in AML: a treatment option?
- (2015) G. Huls BLOOD
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Preclinical studies of 5-fluoro-2′-deoxycytidine and tetrahydrouridine in pediatric brain tumors
- (2015) Marie Morfouace et al. JOURNAL OF NEURO-ONCOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model
- (2015) L. Wang et al. Cancer Immunology Research
- Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
- (2015) B. Boyerinas et al. Cancer Immunology Research
- Alterations of immune response of non-small cell lung cancer with Azacytidine
- (2015) John Wrangle et al. Oncotarget
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
- (2013) Felicetto Ferrara HEMATOLOGICAL ONCOLOGY
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity
- (2012) Amir A. Toor et al. BRITISH JOURNAL OF HAEMATOLOGY
- Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice
- (2012) Pierre L. Triozzi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Inhibition of Histone Lysine Methylation Enhances Cancer-Testis Antigen Expression in Lung Cancer Cells: Implications for Adoptive Immunotherapy of Cancer
- (2011) M. Rao et al. CANCER RESEARCH
- Role of Gene Methylation in Antitumor Immune Response: Implication for Tumor Progression
- (2011) Alfonso Serrano et al. Cancers
- Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression
- (2008) Jennifer A. Wargo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Long-term Epigenetic Therapy with Oral Zebularine Has Minimal Side Effects and Prevents Intestinal Tumors in Mice
- (2008) C. B. Yoo et al. Cancer Prevention Research
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now